Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CAPLACIZUMAB-YHDP Cause White blood cell count abnormal? 9 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 9 reports of White blood cell count abnormal have been filed in association with CAPLACIZUMAB-YHDP. This represents 0.6% of all adverse event reports for CAPLACIZUMAB-YHDP.

9
Reports of White blood cell count abnormal with CAPLACIZUMAB-YHDP
0.6%
of all CAPLACIZUMAB-YHDP reports
0
Deaths
2
Hospitalizations

How Dangerous Is White blood cell count abnormal From CAPLACIZUMAB-YHDP?

Of the 9 reports, 2 (22.2%) required hospitalization.

Is White blood cell count abnormal Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CAPLACIZUMAB-YHDP. However, 9 reports have been filed with the FAERS database.

What Other Side Effects Does CAPLACIZUMAB-YHDP Cause?

Product use in unapproved indication (465) Adamts13 activity decreased (136) Off label use (133) Platelet count decreased (126) Epistaxis (123) Fatigue (110) Contusion (86) Injection site pain (74) Headache (71) Adamts13 activity abnormal (63)

What Other Drugs Cause White blood cell count abnormal?

IBRUTINIB (459) PALBOCICLIB (429) RUXOLITINIB (407) RITUXIMAB (348) LENALIDOMIDE (347) PEGFILGRASTIM (245) TOCILIZUMAB (242) FENTANYL (234) FLUOXETINE (232) VENETOCLAX (231)

Which CAPLACIZUMAB-YHDP Alternatives Have Lower White blood cell count abnormal Risk?

CAPLACIZUMAB-YHDP vs CAPMATINIB CAPLACIZUMAB-YHDP vs CAPREOMYCIN CAPLACIZUMAB-YHDP vs CAPSAICIN CAPLACIZUMAB-YHDP vs CAPTOPRIL CAPLACIZUMAB-YHDP vs CARBAMAZEPINE

Related Pages

CAPLACIZUMAB-YHDP Full Profile All White blood cell count abnormal Reports All Drugs Causing White blood cell count abnormal CAPLACIZUMAB-YHDP Demographics